Neurology · Bipolar DisorderTrial Updateclinicalmid-term

AbbVie Initiates Trial for ABBV-932 in Bipolar Disorder Depressive Episodes

The initiation of the ABBV-932 trial represents a significant opportunity for AbbVie to address a critical gap in treatment options for bipolar disorder, a condition affecting a substantial portion of the adult population. Success in this trial could enhance AbbVie's competitive positioning and market share in the neurology therapeutic area.

Importance7/ 10

ActionMonitor

View Company Intelligence

Explore aggregated signals, assets, and competitive context for organizations linked to this signal.

AbbVie6 signalsView page

AutoResearch

Multi-agent research across ingested FDA, EMA, MHRA, PMDA, PubMed, ClinicalTrials.gov, company documents, and Humanexa signals.

Last run 6/19/2026, 6:31:55 AM

Assessment confidence: 65% · The main uncertainty is whether clinical benefit translates into regulatory momentum and guideline influence.

Executive Thesis

Strategic Assessment

Success in this trial could lead to a new treatment option, impacting market dynamics and AbbVie's competitive positioning in the bipolar disorder space. The strongest clinical anchor is Study to Assess the Adverse Events of Oral ABBV-932 in Adult Participants With Depressive Episodes Associated With Bipolar I or II Disorder (ClinicalTrials.gov), entity match (abbvie). In Neurology · Bipolar Disorder, 0 regulatory and 2 competitive items passed relevance filtering for AbbVie.

Competitive Pressure

The most relevant competitive pressure comes from U.S. FDA Approves Pfizer’s HYMPAVZI for the Treatment of Two Additional Hemophilia A or B Patient Populations with Significant Medical Need (Pfizer) — sponsor/company relevance (pfizer). Secondary pressure from Roche's ENSPRYNG shows 68% relapse reduction in Phase III MOGAD study.

Regulatory Outlook

Regulatory risk is concentrated around The trial's outcomes will be crucial for future regulatory submissions, influencing approval timelines and labeling for ABBV-932 as a treatment for bipolar depression..

Key Risks

Elevated medium regulatory exposure for AbbVie could delay market entry or constrain labeling if agency review intensifies.
Evidence gap: no medium- or high-relevance regulatory precedents in ingested corpus.

Key Opportunities

If successful, ABBV-932 could capture market share in a segment with limited effective therapies, potentially leading to substantial revenue growth for AbbVie.
Upside for AbbVie may improve if A Clinical Trial of Multiple Doses of GR2301 Injection Combined With Phototherapy in Trial Participants With Vitiligo (ClinicalTrials.gov) delivers favorable follow-through.
Success in this trial could lead to a new treatment option, impacting market dynamics and AbbVie's competitive positioning in the bipolar disorder space.

What Would Change This Assessment

This becomes more urgent if Monitor enrollment progress, interim results, and any safety signals reported during the trial.
Timeline shift beyond mid term would change urgency.
A competitor label expansion or pivotal readout in the same sub-indication would increase competitive pressure.

Supporting Evidence

No evidence in this category.

Study to Assess the Adverse Events of Oral ABBV-932 in Adult Participants With Depressive Episodes Associated With Bipolar I or II Disorder
ClinicalTrials.govhigh relevance
Entity match (abbvie)
FDA document
View source
A Study to Assess Adverse Events and Effectiveness of Gel Stent (XEN63) Implantation Using Ab Interno and Ab Externo Approaches in Adult Participants With Glaucoma
ClinicalTrials.govhigh relevance
Entity match (abbvie)
FDA document
View source
Double-blind, Randomized, Placebo-controlled, Multicenter Study to Evaluate the Efficacy and Safety of Ravulizumab Administered Intravenously in Adult Participants at High Risk of Delayed Graft Functi
ClinicalTrials.govhigh relevance
Entity match (adult participants)
FDA document
View source
A Trial to Test if TEV-56286 is Effective for Treatment of Participants With Multiple System Atrophy
ClinicalTrials.govhigh relevance
Entity match (adult participants)
FDA document
View source
Study of Efficacy, Safety and Tolerability of Remibrutinib in Adult Participants With an Allergy to Peanuts
ClinicalTrials.govhigh relevance
Entity match (adult participants)
FDA document
View source
A Clinical Trial of Multiple Doses of GR2301 Injection in Healthy Adult Trial Participants in China.
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single- and Multiple-Ascending Doses and Food Effect of BGB-45035 in Healthy Participants and in Adults With Aut
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
A Clinical Trial of Multiple Doses of GR2301 Injection Combined With Phototherapy in Trial Participants With Vitiligo
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source

U.S. FDA Approves Pfizer’s HYMPAVZI for the Treatment of Two Additional Hemophilia A or B Patient Populations with Significant Medical Need
Pfizerhigh relevance
Sponsor/company relevance (Pfizer)
FDA document
View source
Roche's ENSPRYNG shows 68% relapse reduction in Phase III MOGAD study
Humanexa Signalshigh relevance
Sponsor/company relevance (Roche)

Do subjective and objective baseline sleep disturbances predict post-traumatic stress disorder treatment response? A secondary analysis of a randomized controlled trial.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
Safety and immunogenicity of a booster dose of COVAC-2, Sepivac SWE™ adjuvanted SARS-CoV-2 recombinant protein vaccine in previously vaccinated healthy adults; a randomized controlled multicentre tria
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
Two-week essential oil inhalation treatment modulates the cortisol awakening response and improves self-reported symptoms in stressed adults.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
Safety and durability of influenza and SARS-CoV-2 antibody responses through 6 months after a single dose of mRNA-1083, a multicomponent influenza and COVID-19 vaccine, in adults ≥50 years.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
Immune correlates analysis in NextCOVE trial for a next-generation mRNA-1283 COVID-19 vaccine.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source

Regunera

Precedents · guidance

Reg

Loading regulatory precedents…

View full regulatory analysis

Competitiva

Competitors · threats

Intel

Loading competitive findings…

View full competitive analysis

Why this matters

Affected entities

AbbVie
ABBV-932
bipolar disorder market
adult participants
clinical trial sites

Commercial impact

high

If successful, ABBV-932 could capture market share in a segment with limited effective therapies, potentially leading to substantial revenue growth for AbbVie.

Regulatory impact

medium

The trial's outcomes will be crucial for future regulatory submissions, influencing approval timelines and labeling for ABBV-932 as a treatment for bipolar depression.

What to watch

Monitor enrollment progress, interim results, and any safety signals reported during the trial.

Recommended action

Monitor

Track for follow-up milestones; no immediate action required.